Mutant activin-like kinase 2 in fibrodysplasia ossificans progressiva are activated via T203 by BMP type II receptors

Molecular Endocrinology

Volumn 29, Issue 1, 2015, Pages 140-152

  Fujimoto, Mai ^a,b   Ohte, Satoshi ^a   Osawa, Kenji ^a   Miyamoto, Arei ^a   Tsukamoto, Sho ^a   Mizuta, Takato ^a   Kokabu, Shoichiro ^a,c   Suda, Naoto ^b   Katagiri, Takenobu ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b MEIKAI UNIVERSITY SCHOOL OF DENTISTRY   (Japan)

^c KYUSHU DENTAL COLLEGE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN RECEPTOR 2; BONE MORPHOGENETIC PROTEIN RECEPTOR 1; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; GLYCINE; MUSCLE PROTEIN; MUTANT ACTIVIN LIKE KINASE 2; SERINE; SMAD1 PROTEIN; SMAD5 PROTEIN; THREONINE; UNCLASSIFIED DRUG; ACTIVIN RECEPTOR 1; ACVR1 PROTEIN, MOUSE; SMAD1 PROTEIN, MOUSE; SMAD5 PROTEIN, MOUSE;

ANIMAL CELL; ARTICLE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FIBRODYSPLASIA OSSIFICANS PROGRESSIVA; GENE OVEREXPRESSION; INTRACELLULAR SIGNALING; MOUSE; MYOBLAST; NONHUMAN; OSSIFYING MYOSITIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ANIMAL; BIOSYNTHESIS; CELL DIFFERENTIATION; CELL LINE; GENETICS; METABOLISM; MUTATION; PHOSPHORYLATION; PROTEIN TERTIARY STRUCTURE;

ACTIVIN RECEPTORS, TYPE I; ANIMALS; BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE II; CELL DIFFERENTIATION; CELL LINE; MICE; MUTATION; MYOBLASTS; MYOSITIS OSSIFICANS; PHOSPHORYLATION; PROTEIN STRUCTURE, TERTIARY; SIGNAL TRANSDUCTION; SMAD1 PROTEIN; SMAD5 PROTEIN;

EID: 84922329721     PISSN: 08888809     EISSN: 19449917     Source Type: Journal    
DOI: 10.1210/me.2014-1301     Document Type: Article

References (43)

1. Katagiri T, Suda T, Miyazono K. The bone morphogenetic proteins. In: Derynck R, Miyazono K, eds. TGF-β Family. New York: Cold Spring Harbor Press; 2008:121-149.
2. Miyazono K, Kamiya Y, Morikawa M. Bone morphogenetic protein receptors and signal transduction. J Biochem. 2010;147:35-51.
3. Nakaoka T, Gonda K, Ogita T, et al. Inhibition of rat vascular smooth muscle proliferation in vitro and in vivo by bone morphogenetic protein-2. J Clin Invest. 1997;100:2824-2832.
4. Wozney JM, Rosen V, Celeste AJ, et al. Novel regulators of bone formation: molecular clones and activities. Science. 1998;242: 1528-1534.
5. Kang Q, Sun MH, Cheng H, et al. Characterization of the distinct orthotopic bone-forming activity of 14 BMPs using recombinant adenovirus-mediated gene delivery. Gene Ther. 2004;11:1312- 1320.
6. Katagiri T, Yamaguchi A, Komaki M, et al. Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage. J Cell Biol. 1994;127:1755-1766.
7. Attisano L, Cárcamo J, Ventura F, Weis FM, Massagué J, Wrana JL. Identification of human activin and TGFβ type I receptors that form heteromeric kinase complexes with type II receptors. Cell. 1993;75: 671-680.
8. Muller TD, Nickel J. Promiscuity and specificity in BMP receptor activation. FEBS Lett. 2012;586:1846-1859.
9. Wrana JL, Attisano L, Wieser R, Ventura F, Massagué J. Mechanism of activation of the TGF-β receptor. Nature. 1994;370:341- 347.
10. Katagiri T, Imada M, Yanai T, Suda T, Takahashi N, Kamijo R. Identification of a BMP-responsive element in Id1, the gene for inhibition of myogenesis. Genes Cells. 2002;7:949-960.
11. Korchynskyi O, ten Dijke P. Identification and functional characterization of distinct critically important bone morphogenetic protein- specific response elements in the Id1 promoter. J Biol Chem. 2002;277:4883-4891.
12. Shin M, Ohte S, Fukuda T, et al. Identification of a novel bone morphogenetic protein (BMP)-inducible transcript, BMP-inducible transcript-1, by utilizing the conserved BMP-responsive elements in the Id genes. J Bone Miner Metab. 2013;31:34-43.
13. Shore EM, Xu M, Feldman GJ, et al. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet. 2006;38:525-527.
14. Kaplan FS, Shen Q, Lounev V, et al. Skeletal metamorphosis in fibrodysplasia ossificans progressiva (FOP). J Bone Miner Metab. 2006;26:521-530.
15. Katagiri T, Tsukamoto S. The unique activity of bone morphogenetic proteins in bone: a critical role of the Smad signaling pathway. Biol Chem. 2013;394:703-714.
16. Fukuda T, Kohda M, Kanomata K, et al. Constitutively activated ALK2 and increased SMAD1/5 cooperatively induce bone morphogenetic protein signaling in fibrodysplasia ossificans progressiva. J Biol Chem. 2008;284:7149-7156.
17. Katagiri T. Heterotopic bone formation induced by bone morphogenetic protein signaling: fibrodysplasia ossificans progressiva. J Oral Biosci. 2010;52:33-41.
18. Katagiri T. Recent topics in fibrodysplasia ossificans progressiva. J Oral Biosci. 2012;54:119-123.
19. Whyte MP, Wenkert D, Demertzis JL, DiCarlo EF, Westenberg E, Mumm S. Fibrodysplasia ossificans progressiva: middle-age onset of heterotopic ossification from a unique missense mutation (c. 974G>C, p.G325A) in ACVR1. J Bone Miner Res. 2012;27:729- 737.
20. Smith KA, Joziasse IC, Chocron S, et al. Dominant-negative ALK2 allele associates with congenital heart defects. Circulation. 2009; 119:3062-3069.
21. Joziasse IC, Smith KA, Chocron S, et al. ALK2 mutation in a patient with Down's syndrome and a congenital heart defect. Eur J Hum Genet. 2011;19:389-393.
22. Fukuda T, Kanomata K, Nojima J, et al. A unique mutation of ALK2, G356D, found in a patient with fibrodysplasia ossificans progressiva is a moderately activated BMP type I receptor. Biochem Biophys Res Commun. 2008;377:905-909.
23. Ohte S, Shin M, Sasanuma H, et al. A novel mutation of ALK2, L196P, found in the most benign case of fibrodysplasia ossificans progressiva activates BMP-specific intracellular signaling equivalent to a typical mutation, R206H. Biochem Biophys Res Commun. 2011;407:213-218.
24. Wieser R, Wrana JL, Massagué J. GS domain mutations that constitutively activate TβR-I, the downstream signaling component in the TGF-β receptor complex. EMBO J. 1995;10:2199-2208.
25. Goldman LA, Cutrone EC, Kotenko SV, Krause CD, Langer JA. Modifications of vectors pEF-BOS, pcDNA1 and pcDNA3 result in improved convenience and expression. Biotechniques. 1996;21: 1013-1015.
26. Kodaira K, Imada M, Goto M, et al. Purification and identification of a BMP-like factor from bovine serum. Biochem Biophys Res Commun. 2006;345:1224-1231.
27. Nojima J, Kanomata K, Takada Y, et al. Dual roles of smad proteins in the conversion from myoblasts to osteoblastic cells by bone morphogenetic proteins. J Biol Chem. 2010;285:15577-15586.
28. Kinoshita E, Kinoshita-Kikuta E, Takiyama K, Koike T. Phosphate- binding tag, a new tool to visualize phosphorylated proteins. Mol Cell Proteomics. 2006;4:749-757.
29. Kinoshita E, Kinoshita-Kikuta E, Koike T. Separation and detection of large phosphoproteins using Phos-tag SDS-PAGE. Nat Protoc. 2009;10:1513-1521.
30. Iguchi M, Kujuro Y, Okatsu K, et al. Parkin-catalyzed ubiquitinester transfer is triggered by PINK1-dependent phosphorylation. J Biol Chem. 2013;30:22019-22032.
31. Okatsu K, Oka T, Iguchi M, et al. PINK1 autophosphorylation upon membrane potential dissipation is essential for Parkin recruitment to damaged mitochondria. Nat Commun. 2012;3:1016.
32. Katagiri T, Osawa K, Tsukamoto S, Fujimoto M, Miyamoto A, Mizuta T. Bone morphogenetic protein-induced heterotopic bone formation: what have we learned from the history of a half century? Doi:10.1016/j.jdsr. 2014.09.004.
33. Suzuki A, Kaneko E, Ueno N, Hemmati-Brivanlou A. Regulation of epidermal induction by BMP2 and BMP7 signaling. Dev Biol. 1997;189:112-122.
34. Zhang D, Schwarz EM, Rosier, RN, Zuscik MJ, Puzas JE, O'Keefe RJ. ALK2 functions as a BMP type I receptor and induces Indian hedgehog in chondrocytes during skeletal development. J Bone Miner Res. 2003;18:1593-1604.
35. Akiyama S, Katagiri T, Namiki M, et al. Constitutively active BMP type I receptors transduce BMP-2 signals without the ligand in C2C12 myoblasts. Exp Cell Res. 1997;2:362-369.
36. Le VQ, Wharton KA. Hyperactive BMP signaling induced by ALK2(R206H) requires type II receptor function in a Drosophila model for classic fibrodysplasia ossificans progressiva. Dev Dyn. 2012;241:200-214.
37. Namiki M, Akiyama S, Katagiri T, et al.Akinase domain-truncated type I receptor blocks bone morphogenetic protein-2-induced signal transduction in C2C12 myoblasts. J Biol Chem. 1997;35: 22046-22052.
38. Ebisawa T, Tada K, Kitajima I, et al. Characterization of bone morphogenetic protein-6 signaling pathways in osteoblast differentiation. J Cell Sci. 1999;20:3519-3527.
39. Luo J, Tang M, Huang J, et al. TGFβ/BMP type I receptors ALK1 and ALK2 are essential for BMP9-induced osteogenic signaling in mesenchymal stem cells. J Biol Chem. 2010;38:29588-29598.
40. Fukuda T, Scott G, Komatsu Y, et al. Generation of a mouse with conditionally activated signaling through the BMP receptor, ALK2. Genesis. 2006;44:159-167.
41. Yu PB, Deng DY, Lai CS, et al. BMP type I receptor inhibition reduces heterotopic [corrected] ossification. Nat Med. 2008;14: 1363-1369.
42. Bagarova J, Vonner AJ, Armstrong KA, et al. Constitutively active ALK2 receptor mutants require type II receptor cooperation. Mol Cell Biol. 2013;33:2413-2424.
43. Haupt J, Deichsel A, Stange K, et al. ACVR1 p.Q207E causes classic fibrodysplasia ossificans progressiva and is functionally distinct from the engineered constitutively active ACVR1 p.Q207D variant. Hum Mol Genet. 2014;23(20):5364-5377.